biostudies-literatureUnknown18(6)Holzhauser SHuman papillomavirus positive (HPV⁺) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have better outcomes than corresponding HPV^- negative (HPV^-) cancer cases. Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) are often mutated in HPV⁺ cancer. To investigate whether targeted therapy is an option for TSCC/BOTSCC, two HPV⁺ and one HPV^- TSCC/BOTSCC cell lines were tested for their sensitivity towards FGFR and PI3K inhibitors. The HPV⁺ cell lines UM-SCC-47 and UPCI-SCC-154, and the HPV^- cell line UT-SSC-60A were tested by competitive allele-specific TaqMan-PCR for presence/absencOncology letters6249-6260https://www.ebi.ac.uk/biostudies/studies/S-EPMC6865836biostudies-literature<i>In vitro</i> antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.PMC6865836Kostopoulou ONBersani COhmayer AWickstrom MRamqvist THolzhauser SAndonova TDalianis TLange BKAfalse<i>In vitro</i> antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines.Human papillomavirus positive (HPV⁺) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have better outcomes than corresponding HPV^- negative (HPV^-) cancer cases. Our previous study demonstrated that fibroblast growth factor receptor 3 (FGFR3) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA) are often mutated in HPV⁺ cancer. To investigate whether targeted therapy is an option for TSCC/BOTSCC, two HPV⁺ and one HPV^- TSCC/BOTSCC cell lines were tested for their sensitivity towards FGFR and PI3K inhibitors. The HPV⁺ cell lines UM-SCC-47 and UPCI-SCC-154, and the HPV^- cell line UT-SSC-60A were tested by competitive allele-specific TaqMan-PCR for presence/absenc2019-01-01T00:00:00Z2019 Dec2025-04-22T00:27:56.386Z2025-04-05T19:33:35.145ZS-EPMC68658363178810210.3892/ol.2019.10973